Cocrystal Development Pipeline
Our development programs include a wide variety of serious and/or chronic viral diseases including influenza, COVID-19, hepatitis C and gastroenteritis caused by norovirus.
Program | Discovery | Preclinical | Phase 1 | Phase 2a | Phase 2b | Phase 3 | |
---|---|---|---|---|---|---|---|
Influenza A | CC-42344 oral PB2 Inhibitor |
Discovery Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2a Phase complete
|
Phase 2b Phase complete
|
Phase 3 Phase complete
|
Influenza A/B
In collaboration with ![]() |
Influenza A/B Inhibitor |
Discovery Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2a Phase complete
|
Phase 2b Phase complete
|
Phase 3 Phase complete
|
Influenza A | CC-42344 Inhaled PB2 inhibitor |
Discovery Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2a Phase complete
|
Phase 2b Phase complete
|
Phase 3 Phase complete
|
COVID-19 | CDI-988 Oral Protease Inhibitor |
Discovery Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2a Phase not started
|
Phase 2b Phase not started
|
Phase 3 Phase not started
|
COVID-19 (Licensed) | CDI-45205 Protease Inhibitor |
Discovery Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2a Phase not started
|
Phase 2b Phase not started
|
Phase 3 Phase not started
|
COVID-19 | Replication Inhibitors |
Discovery Phase in progress
|
Preclinical Phase not started
|
Phase 1 Phase not started
|
Phase 2a Phase not started
|
Phase 2b Phase not started
|
Phase 3 Phase not started
|
Norovirus Gastroenteritis | CDI-988 Oral Protease Inhibitor |
Discovery Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2a Phase not started
|
Phase 2b Phase not started
|
Phase 3 Phase not started
|